The Web Health



Name of the generic: tagraxofusp [tag-RAX-ohfusp] [tag-RAX-oh-fusp]
The brand name is Elzonris.
Dosage forms: intravenous solution (1000 mg/mL)
The class of drug: miscellaneous antineoplasticsb

What is Tagraxofusp?

Tagraxofusp is a treatment for the blastic plasmacytoid neoplasm of dendritic cells, which is a rare blood or bone marrow cancer. Tagraxofusp can be used by the adult population and in children of two years of age or older. Tagraxofusp can also be used to treat conditions that are not mentioned in this guide.

Side effects of Tagraxofusp

Seek medical attention immediately. If you are experiencing symptoms that indicate an allergic reaction, such as itching, rash, and mouth sores, an intense tingling or warmth, difficulty breathing, or swelling of your lips, face, or tongue.

Capillary leak syndrome can be a severe adverse effect associated with tagraxofusp. Call your doctor immediately if you experience an irritable or running nose, and follow up with:

  • Dizziness, or tiredness;
  • Thirst;
  • Reduced urination
  • Trouble breathing trouble breathing
  • Sudden swelling or weight gain.

Common side effects of tagraxofusp include:

  • Capillary leak syndrome
  • Nausea;
  • Tiredness;
  • Swelling of your feet or hands;
  • Fever or
  • Weight gain.

This isn't an exhaustive list of possible side effects, and other side effects could occur. Consult your physician to seek medical advice on adverse effects. You can report any symptoms to the FDA at 1-800-FDA-1088.


Consult your physician right now if you notice indications of a dangerous condition known as capillary leak syndrome. running or stuffy nose that is followed by fatigue, dizziness, thirst, a decrease in urine output, breathing difficulties, and sudden swelling or weight growth.

Before you take this drug

It is possible that you will need to take an unfavourable pregnancy test one week prior to beginning this treatment. Tagraxofusp can harm a newborn baby. Use effective birth control to avoid pregnancy while you're using Tagraxofusp for at least one week following your last dose. Avoid breastfeeding during the course of this medication and for at least one week following your last dose.

How to take tagraxofusp?

The doctor will conduct blood tests to confirm that you don't have any issues that could make it unsafe for you to use tagraxofusp. Tagraxofusp is administered as an injection into the vein. The healthcare professional will give the injection. It is possible to receive this medication in a clinic or hospital setting to help treat severe negative side effects. There are other medicines to prevent severe reactions or allergic reactions. Continue to take these medications for the duration your doctor has prescribed. Tagraxofusp is administered as part of a 21-day treatment. It is possible that you will need to take the medication only for the initial 5 days of every cycle. Your physician will decide the duration of treatment with this medication. It is possible that you will require frequent medical tests to make sure the medication isn't creating harmful side effects. Treatment for cancer could be delayed or discontinued permanently, depending on the results.

Details on dosage

Usual Adult Dose for Malignant Disease:

12 mcg/kg IV administered over 15 minutes every day from Days 1 to 5 of a 21-day regimen until the disease progresses or there are unacceptable toxicities

Premedicate patients by using the H1-histamine antagonist (e.g., diphenhydramine) or an antagonist of H2-histamine (e.g., ranitidine) and corticosteroids (e.g., 50 mg intravenous of methylprednisolone (or equivalent)) and acetaminophen about sixty minutes before every infusion.
The time for dosing can be extended to accommodate delays in doses up to Days 10 and 11 of the cycle.

Use: To treat blastic plasmacytoid-dendritic cell neoplasm (BPDCN)

Usual Paediatric Dose for Malignant Disease:

2 years old and over:
12 mg/kg IV for 15 minutes every day between days 1 and 5 of a 21-day course until the disease progresses or there are unacceptable levels of toxicity.

Premedicate patients using one of the antagonists for H1 (e.g., diphenhydramine), an H2-histamine antagonist (e.g., ranitidine), a corticosteroid (e.g., 50 mg of methylprednisolone IV or comparable), and acetaminophen for approximately 60 minutes prior to the infusion.
The dosing time can be extended in case of dosage delays until day 10 of the course.

Use: To treat blastic plasmacytoid-dendritic cell cancer (BPDCN) in children two years old and over.

What happens If I miss a dose?

Contact your doctor for advice in the event that you don't make an appointment to receive the injection of tagraxofusp.

What happens if I overdose?

Since the drug is administered by a health expert in a medical environment, there is no risk of overdose.

What should be avoided?

Follow the instructions of your physician regarding any limitations on foods, drinks, or any activity.

Interaction with other drugs

Other drugs can interact with tagraxofusp's effects, including medications that are prescribed and available over the counter, vitamins, and herbal products. Discuss with your doctor all the medications you currently use and any medications you begin or stop taking.